COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,612 Articles (22,913 medRxiv, 8,699 bioRxiv)

Most recent first Previous |  Page 1349: Articles 13481-13490  | Next

High vaccine effectiveness against COVID-19 infection and severe disease among residents and staff of long-term care facilities in Norway, November - June 2021
Starrfelt, J., Danielsen, A. S., Kacelnik, O., Borseth, A. W., Seppala, E., Meijerink, H.
10.1101/2021.08.08.21261357 — Posted: 2021-08-09
Limited genomic reconstruction of SARS-CoV-2 transmission history within local epidemiological clusters
Gallego-Garcia, P., Varela, N., Estevez-Gomez, N., De Chiara, L., Fernandez-Silva, I., Valverde, D., Sapoval, N., Treangen, T., Regueiro, B., Cabrera-Alvargonzalez, J. J., del Campo, V., Perez, S., Posada, D.
10.1101/2021.08.08.21261673 — Posted: 2021-08-09
Time-analysis of COVID-19 dispersion among health care workers and the general population
Leme, P. A. F., Jalalizadeh, M., Dionato, F. A. V., Buosi, K., Dal Col, L. S. B., Giacomelli, C. F., Ferrari, K. L., Pagliarone, A. C., Gon, L. M., Maia, C. L., Esfahani, A. A., Reis, L. O.
10.1101/2021.08.07.21261433 — Posted: 2021-08-09
Speeding and Traffic-Related Injuries and Fatalities during the 2020 COVID-19 Pandemic: The Cases of Seattle and New York City
Liao, H., Lowry, M.
10.1101/2021.08.08.21261745 — Posted: 2021-08-09
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients
Henriquez, S., Zerbit, J., Bruel, T., Ouedrani, A., Planas, D., Deschamps, P., Staropoli, I., Hadjadj, J., Varet, B., Suarez, F., Ermak, N., Bouscary, D., Willems, L., Fouquet, G., Decroocq, J., Franchi, P., Deau-Fischer, B., Terrier, B., Tamburini, J., Chatenoud, L., Schwartz, O., Vignon, M.
10.1101/2021.08.08.21261769 — Posted: 2021-08-09
Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised Patients
Hadjadj, J., Planas, D., Ouedrani, A., Buffier, S., Delage, L., Nguyen, Y., Bruel, T., Stolzenberg, M.-C., STAROPOLI, I., Ermak, N., Macraigne, L., Morbieu, C., Henriquez, S., Veyer, D., Pere, H., Casadevall, M., Mouthon, L., Rieux-Laucat, F., Chatenoud, L., Schwartz, O., Terrier, B.
10.1101/2021.08.08.21261766 — Posted: 2021-08-09
Internet Use impact on Physical Health during COVID-19 pandemic in Bangladesh: A Web-based Cross-sectional study
ABIR, T. F., Osuagwu, U. L., Nur -A Yazdani, D. M., Mamun, A. A. M. A., Kakon, K., Salamah, A. A., Zainol, N. R., Khanam, M., Agho, K. E.
10.1101/2021.08.06.21261689 — Posted: 2021-08-09
Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine in High-Risk Occupational Population: a randomized, parallel, controlled clinical trial
Feng, Y., Chen, J., Yao, T., Chang, Y., Li, X., Xing, R., Li, H., Xie, R., Zhang, X., Wei, Z., Mu, S., Liu, L., Feng, L., Wang, S.
10.1101/2021.08.06.21261696 — Posted: 2021-08-09
COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort Study
Patel, N. J., D'Silva, K. M., Hsu, T. Y.- T., DiIorio, M. A., Fu, X., Cook, C. E., Prisco, L. C., Martin, L. W., Vanni, K. M. M., Zaccardelli, A., Zhang, Y., Sparks, J. A., Wallace, Z. S.
10.1101/2021.08.05.21261643 — Posted: 2021-08-09
Durability and Cross-Reactivity of Immune Responses Induced by an AS03 Adjuvanted Plant-Based Recombinant Virus-Like Particle Vaccine for COVID-19
Gobeil, P. A. M., Pillet, S., Boulay, I., Charland, N., Lorin, A., Cheng, M., Vinh, D., Boutet, P., Van Der Most, R., Roman, F., de los Angeles Ceregido Perez, M., D'Aoust, M.-A., Landry, N., Ward, B.
10.1101/2021.08.04.21261507 — Posted: 2021-08-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).